Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments The acquisition will expand Otsuka’s continued investment in emerging, next-generation neuropsychiatric treatments for serious mental illness June 12, 2026